BioSpace News Archive

AIM ImmunoTech Inc. announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for MRT-2359, a potent and selective GSPT1-directed MGD.

Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced that management will participate in the Lake Street Best Ideas Growth Conference, which is being held at The Yale Club in New York, NY on Wednesday, September 14th.

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the 24th Annual H.C. Wainwright Global Investment Conference.

SPR Therapeutics announced the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System.

Impel Pharmaceuticals Inc. announced that the Company will participate in two upcoming investor conferences in September.

Protalix BioTherapeutics, Inc. announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris from September 9-13, 2022.

QuantuMDx Group Limited, announces it has entered into a cooperation agreement with Sansure Biotech Inc., an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC™ and its assays, in China.